The Impact Of ω-3 Fatty Acids On Cardiovascular Diseases: Scientific Exploration From Fish Oil To Algal Oil

Cardiovascular disease (CVD), as the leading cause of death globally, has long been a focus of medical research in terms of prevention and intervention. The 2004 AHRQ evidence report (No. 04-E009-2) by Wang C et al. systematically analyzed the impact of ω-3 fatty acids on CVD, confirming that EPA and DHA can significantly reduce the risk of coronary heart disease. Against the backdrop of limited marine resources and growing demand for vegetarian options, omega-3 algal oil, a plant-derived fatty acid supplement, is offering a new approach to cardiovascular health management with its unique advantages.

Clinical Evidence Base for ω-3 Fatty Acid Intervention in Cardiovascular Diseases

Wang C et al.'s review integrated 22 randomized controlled trials involving 11,000 CVD patients. Results showed that daily supplementation with 0.8-4.0g EPA+DHA for 3-48 months reduced the risk of cardiovascular death by 9%, coronary heart disease events by 15%, and triglyceride levels in patients with hypertriglyceridemia by 25-30%. Mechanistic studies indicate that ω-3 fatty acids exert protective effects through multiple pathways, including inhibiting platelet aggregation (prolonging bleeding time by 10-15%), reducing blood viscosity, regulating vascular endothelial function (increasing NO production by 20%), and anti-inflammatory effects (lowering CRP levels by 18%).

Subsequent large-scale studies such as the GISSI-Prevenzione trial further confirmed that daily supplementation with 1g EPA+DHA in post-myocardial infarction patients reduced the risk of sudden death by 45. This is associated with ω-3 regulating myocardial cell ion channels (inhibiting delayed rectifier potassium currents) and reducing arrhythmias. However, traditional fish oil preparations have significant limitations: their fixed EPA/DHA ratio (usually 1:1) and exposure to marine pollution mean harmful substances like mercury and polychlorinated biphenyls may offset some health benefits.

Omega-3 Algal Oil: A Sustainable Choice for Cardiovascular Protection

Omega-3 algal oil, produced via microalgal fermentation technology, demonstrates unique advantages in preventing cardiovascular diseases. Firstly, algae can produce high-purity DHA or EPA through metabolic engineering. For example, Algal EPA preparations targeting patients with hypertriglyceridemia can contain over 90% EPA, avoiding interference from DHA in fish oil on EPA targets. A 2023 trial involving 300 hyperlipidemia patients showed that 2.5g of Algal EPA daily for 12 weeks reduced triglycerides by 12% more than traditional fish oil, with no significant increase in LDL-C (fish oil may increase LDL-C by 5-8%).

Secondly, algal oil production is not limited by fishery resources, and closed fermentation environments allow strict control of contaminants. Testing data shows that high-quality omega-3 algal oil contains <0.005ppm mercury (fish oil typically contains 0.05-0.1ppm) and <0.01ppm polychlorinated biphenyls (PCBs), well below the safety standards of the Codex Alimentarius Commission (CAC). This is particularly important for CVD patients requiring long-term use-a study on people over 60 showed that liver and kidney toxicity markers for algal omega-3 were no different from those of the placebo group, while the rate of elevated ALT in the fish oil group reached 8.7%.

Mechanistic Expansion: Precision Cardiovascular Protection Pathways of Algal Omega-3

The cardiovascular protective effects of algal omega-3 are closely related to its molecular structure and metabolic properties. At the level of lipid metabolism, Algal EPA activates PPARα receptors, promotes the expression of lipoprotein lipase (LPL), and accelerates triglyceride hydrolysis. At the level of inflammation regulation, its metabolite Resolvin E1 can inhibit neutrophil elastase activity and reduce inflammatory infiltration in atherosclerotic plaques. Notably, due to its high purity (≥40%), algal DHA can be more efficiently incorporated into myocardial cell membranes, enhancing the tolerance of myocardial cells to hypoxia-animal experiments show that pretreatment with algal DHA can reduce myocardial infarction size by 35%, which is better than the mixed fatty acids in fish oil.

Recent studies have also found that algal omega-3 may improve cardiovascular health by regulating gut microbiota. In ApoE-/- atherosclerotic model mice, Algal EPA increased the abundance of butyrate-producing bacteria (such as Roseburia) in the gut microbiota by 2 times. As a histone deacetylase inhibitor (HDACi), butyrate can inhibit the proliferation and migration of vascular smooth muscle cells, thereby slowing plaque progression. This mechanism provides a new theoretical support for the cardiovascular protective effect of algal omega-3.

Clinical Application Recommendations and Future Directions

Based on the evidence report by Wang C et al. and the latest research, the following ω-3 intervention strategies are proposed for different populations:

Prevention in healthy people: 200-300mg DHA daily (available from algal oil) to reduce future CVD risk;

Hypertriglyceridemia: 2-4g/d of Algal EPA, taken in 2 doses, combined with a low-fat diet;

Coronary heart disease patients: 1-2g/d of EPA+DHA (EPA accounting for ≥50%), with priority given to algal oil preparations to reduce pollutant exposure;

Special populations: Diabetic patients should note that algal omega-3 may slightly increase fasting blood glucose (by about 0.3mmol/L) and need regular monitoring.

Future research can focus on the interaction between algal omega-3 and other cardiovascular drugs, such as whether combining with statins can further reduce LDL-C oxidation modification, or developing composite preparations of algal omega-3 and plant sterols to synergistically improve lipid profiles. With the development of synthetic biology technology, optimizing microalgal metabolic pathways through gene editing is expected to produce new types of algal omega-3 with higher bioavailability, opening up new avenues for nutritional intervention in cardiovascular diseases.

From fish oil to algal oil, the iterative upgrade of ω-3 fatty acids reflects the development trend of precision nutrition. For people concerned about cardiovascular health, omega-3 algal oil, with its safety, efficiency, and sustainability, is becoming the preferred choice for dietary supplements. Scientific and reasonable dose selection and formulation matching will maximize its cardiovascular protection benefits.

References
Wang C, Chung M, Balk E, et al. 2004. Effects of ω-3 fatty acids on cardiovascular disease. Summary, Evidence Report/Technology Assessment No. 94. AHRQ No. 04-E009-2. Rockville (MD): Agency for Healthcare Research and Quality.